Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.

In 2004, Biovitrum started to manufacture the active protein component for Wyeth’s (now Pfizer’s) ReFacto® and ReFacto/Xyntha® drugs for treatment of hemophilia, and marketing of specialty pharmaceuticals (ReFacto, Mimpara and Kineret®) was initiated in the Nordic region.

This partnership was extended the following year to also include the development of a long-lasting recombinant factor VIII Fc fusion protein candidate, rFVIIIFc, for the treatment of hemophilia A.

In 2008, an agreement with Amgen regarding the acquisition of the products Kepivance and Stemgen as well as a global license for Kineret was signed In 2009, Sobi and partner Biogen Idec took the decision to enter final registration studies for the recombinant factor FIXFc.

[7][8] Sobi is an international specialty healthcare company dedicated to rare diseases with a focus on treatments in haematology, immunology and speciality care.